Results were similar for breast cancer-specific survival, except that African Americans and non-Hispanic Whites living in high-SES neighborhoods had similar survival.Strategies to address the underlying factors that may influence treatment intensity and adherence, such as comorbidities and logistical barriers, should be targeted at low-SES non-Hispanic White and all African American patients. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Halley, M. C., May, S. G., Rendle, K. A., Frosch, D. L., Kurian, A. W. Obesity and Mortality After Breast Cancer by Race/Ethnicity: The California Breast Cancer Survivorship Consortium. Understanding of risk and patient factors (e.g. Worry in the long-term survivorship period was higher among those with unmet need for discussion (48.7% v 24.9%; P Rates of patient portal messaging did not differ between English-speaking and LEP groups on multivariable analysis; however, patients with LEP were less likely to have a portal account (adjusted OR, 0.89; 95% CI, 0.83 to 0.96). Future work should explore reasons behind the high levels of sexual dysfunction and unmet needs in female survivors.It is important to routinely screen for sexual health concerns among female cancer survivors at all phases of the cancer trajectory including years posttreatment. See the full leadership team at Craft. Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative. Forty-three percent of the patients were treated at the academic center only, 42 percent at the community center only, and 16 percent of the patients obtained care at both health care organizations. Candidate polygenic risk scores (PRSs) as predictors of personal breast cancer history were developed through multivariable logistic regression models adjusted for age, cancer history, and ancestry. Feb 27 Google Public Sector is working with @ALPLM to help bring history to life by creating engaging experiences for visitors with AI, extended reality & AR technologies. Call Us: +91 93400 39618 Home; About Us; Admission; Infrastructure; Academic; Gallery; Contact Us; glasgow gangland news Menu Close. A., Teo, S. H., Teras, L. R., Terry, M. B., Toland, A. E., Tomlinson, I., Truong, T., Tseng, C. C., Untch, M., Vachon, C. M., van den Ouweland, A. M., Wang, S. S., Weinberg, C. R., Wendt, C., Winham, S. J., Winqvist, R., Wolk, A., Wu, A. H., Yamaji, T., Zheng, W., Ziogas, A., Pharoah, P. D., Dunning, A. M., Easton, D. F., Pettitt, S. J., Lord, C. J., Haider, S., Orr, N., Fletcher, O. Gallagher, S., Hughes, E., Kurian, A. W., Domchek, S. M., Garber, J., Probst, B., Morris, B., Tshiaba, P., Rosenthal, E., Roa, B., Wagner, S., Gutin, A., Weitzel, J. N., Lanchbury, J., Robson, M. E. Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site. Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions. Half (54.7%) used AIs only, 27.6% used tamoxifen only and 17.7% used both tamoxifen and AIs sequentially. Halley, M., May, S., Rendle, K., Frosch, D., Kurian, A. W. Male breast cancer: a comparison between BRCA mutation carriers and non-carriers in Hong Kong, Southern China, Kwong, A., Chau, W., Law, F., Kurian, A. W., et al, A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Wu, J., Cui, Y., Sun, X., Cao, G., Li, B., Ikeda, D. M., Kurian, A. W., Li, R. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Allison W. Kurian, M.D., M.Sc. Goodness-of-fit tests showed that the MA-PRS was well calibrated and predicted BC risk accurately in the tails of the distribution for both European and non-European women.The MA-PRS uses genetic ancestral composition to expand the utility of polygenic risk prediction to non-European women. Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P=.29). Crown, A., Fazeli, S., Kurian, A. W., Ochoa, D. A., Joseph, K. A. Genome-Wide Analyses Characterize Shared Heritability Among Cancers and Identify Novel Cancer Susceptibility Regions. Factors associated with 21-gene assay uptake were identified using a multivariable logistic regression model.Uptake of the 21-gene assay increased over time and differed by race, socioeconomic status (SES), and age. Schackmann, E. A., Vinayak, S., Kurian, A. W., et al. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. Recurrence risk perception and quality of life after treatment of breast cancer, Hawley, S., Janz, N., Jagsi, R., Griffith, K., Friese, C., Kurian, A. W., et al. We compared the ability of each NLP model to identify the presence, timing, and site of recurrence, when compared against manual chart review and International Classification of Diseases coding.A total of 1,273 patients were included in the development and validation of the two models. Under his leadership, that business became the company's fastest-growing business and the industry's leading middleware product suite. Liang, S., Richardson, M., Chen, T., Colocci, N., Kurian, A., de Briun, M., Chan, C., Chan, J. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., Katz, S. J. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. Among adopters, 52% initiated coverage pre-NCD over a 25-month period and 48% post-NCD over 17 months.We found an increase, but continued variability, in coverage over 3.5 years. [10] In 2014, she conducted a study with Scarlett Gomez which found that breast cancer patients who undergo bilateral mastectomy are not guaranteed better survival rates. Their application to women of non-European ancestry has lagged because of the lack of a formal approach to incorporate genetic ancestry and ancestry-dependent variant frequencies and effect sizes. Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer, Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. Schapira, L., Hofmeister, E., Kurian, A. W., Zion, S., Shen, H., Torres, T., Berek, J. S., Palesh, O. Associations between CPM receipt and surgeon recommendations were also evaluated. Results did not vary by diagnosis year.Among patients with high genetic risk, clinicians' recommendations, potential treatment implications, and protections against discrimination were motivating factors to undergo genetic testing, but fewer than half recalled clinicians providing all this information, and this did not improve over time. Katz, S., Friese, C., Li, Y., Deapen, D., Hamilton, A., Ward, K., Kurian, A. W. Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer. Given the specialized counseling and testing needs of patients with Li-Fraumeni syndrome, and the implications for targeted screening strategies if a mutation is found, referral to a cancer genetics expert is strongly recommended. We propose an efficient natural language processing approach for inferring the BI-RADS final assessment categories by analyzing only the mammogram findings reported by the mammographer in narrative form. View details for DOI 10.1200/CCI.20.00165. After controlling for patient and tumor characteristics, second opinion use was not associated with chemotherapy receipt (OR, 1.04; 95% CI, 0.71-1.52).Second opinion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfaction regardless of second opinion use suggests little unmet demand. Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., Ford, J. M. Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. Compared with breast-conserving surgery with radiation (10-year mortality, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32-1.39]; 10-year mortality, 20.1% [95% CI, 19.9%-20.4%]). A combined risk score (CRS) of an 86-single-nucleotide polymorphism polygenic risk score and the Tyrer-Cuzick v7.02 clinical risk estimator was generated with attenuation for confounding by family history. Allison W. Kurian, M.D., M.Sc. Multivariable models evaluated correlates of a strong desire for genetic testing, unmet need for discussion with a health care professional, and receipt of testing.Among 1,536 patients who completed the survey, 35% expressed strong desire for genetic testing, 28% reported discussing testing with a health care professional, and 19% reported test receipt. We compared breast cancer-specific and overall survival time after nipple-sparing versus non-nipple-sparing mastectomy, using multivariable analysis.Among 157,592 stage 0-III female breast cancer patients treated with unilateral mastectomy from 1988-2013, 993 (0.6%) were reported as having nipple-sparing and 156,599 (99.4%) non-nipple-sparing mastectomies; median follow-up was 7.9years. Population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and management in women with inherited pathogenic variants.In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. View details for DOI 10.1038/s41431-021-00987-7, Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. View details for DOI 10.1007/s10689-012-9577-8. In the past decade, there has been a surge both in genetic testing technology and in patient access to such testing. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. The early months of the COVID-19 pandemic led to reduced cancer screenings and delayed cancer surgeries. Kurian, A. W., Canchola, A. J., Ma, C. S., Clarke, C. A., Gomez, S. L. Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. View details for DOI 10.1016/j.gygno.2004.10.037, View details for Web of Science ID 000226636600041. While free-text clinic notes may offer the greatest nuance and detail about a patient's clinical status, they are largely excluded in previous predictive models due to the increase in processing complexity and need for a complex modeling framework. RATIONALE: Estrogen can cause the growth of breast cancer cells. Talking about her educational background, well, she is a high school graduate. Mean HRD-LOH scores were higher in responders compared with nonresponders (P = .02) and remained significant when BRCA1/2 germline mutations carriers were excluded (P = .021).Preoperative combination of gemcitabine, carboplatin, and iniparib is active in the treatment of early-stage triple-negative and BRCA1/2 mutation-associated breast cancer. evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine Multi-step processing, including deep-learning-based segmentation, revealed variability in the composition of tumor-immune populations across individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune subpopulations and checkpoint expression. Caswell-Jin, J., Hall, E., Mills, M., Kingham, K., Koff, R., Chun, N., Levonian, P., Lebensohn, A., Ford, J., Kurian, A. W. Jagsi, R. n., Abrahamse, P. H., Lee, K. L., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M. n., Kurian, A. W., Friese, C. R., Hawley, S. T., Katz, S. J. We report lavage of fluid-yielding and non-fluid-yielding ducts in women at high inherited breast cancer risk.A pilot breast cancer screening study including ductal lavage was conducted in 75 women at high inherited risk, 56 (74.7%) of whom had BRCA1/2 mutations. Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women. Charges, claims, and reimbursements are related to cost but are nontransparent and proprietary. Associations between sociodemographic and clinical factors and GCC receipt were examined.Most YAs were 35 to 39years old (51.2%) and partnered (56.4%); half had hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors. Relative to high-socioeconomic status (SES) non-Hispanic Whites, we observed less anthracycline and taxane use by SES non-Hispanic Whites (OR 0.63, 95 % CI 0.49-0.82) and American Indians (OR 0.23, 95 % CI 0.06-0.93), and more anthracycline use by high-SES Asians/Pacific Islanders (OR 1.72, 95 % CI 1.02-2.90). We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk. Symptoms and survivorship needs differences between "good sleepers" and "bad sleepers" in survivors of breast and gynecologic cancers. Banerjee, I., Bozkurt, S., Alkim, E., Sagreiya, H., Kurian, A. W., Rubin, D. L. Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. not yet known whether letrozole is more effective than a placebo in treating patients with For more information, please contact Amy Isaacson, 650-723-0501. (IV) infusions (followed by vinorelbine) and conventional sequential administration of We sought to assess the impact of primary language on health care engagement as indicated by clinical trial screening and engagement, use of genetic counseling, and communication via an electronic patient portal.Clinical and demographic data on patients with breast cancer diagnosed and treated from 2013 to 2018 within the Stanford University Health Care system were compiled via linkage of electronic health records, an internal clinical trial database, and the California Cancer Registry. Lu, Y., John, E. M., Sullivan-Halley, J., Vigen, C., Gomez, S. L., Kwan, M. L., Caan, B. J., Lee, V. S., Roh, J. M., Shariff-Marco, S., Keegan, T. H., Kurian, A. W., Monroe, K. R., Cheng, I., Sposto, R., Wu, A. H., Bernstein, L. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Treatment and monitoring options for patients with metastatic breast cancer (MBC) are increasing, but little is known about variability in care. For patients carrying a VUS, clinical documentation was assessed for evidence of provider awareness of the conflict.50/975 (5.1%) patients with non-negative results carried a variant with a clinically significant conflict, 19 with a P/LP variant reported in APC or MUTYH, and 31 with a VUS reported in CDKN2A, CHEK2, MLH1, MSH2, MUTYH, RAD51C, or TP53. Friese, C. R., Li, Y., Bondarenko, I., Hofer, T. P., Ward, K. C., Hamilton, A. S., Deapen, D., Kurian, A. W., Katz, S. J. (PsycInfo Database Record (c) 2022 APA, all rights reserved). Little is known about its long-term performance in a racially/ethnically diverse population.The Women's Health Initiative study enrolled postmenopausal women from 1993-1998. of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line One-third (33%) received chemotherapy. Through recursive partitioning, the highest mastectomy subgroups were defined by tumor characteristics such as size and anatomic location, in combination with diagnosis year and nativity.Tumor characteristics and, secondarily, patient, hospital, and neighborhood factors are predictors of mastectomy and omission of radiation following BCS among Asian Americans.By focusing on interactions among patient, hospital, and neighborhood factors in the differential receipt of breast cancer treatment, our study identifies subgroups of interest for further study and translation into public health and patient-focused initiatives to ensure that all women are fully informed about treatment options. Hla genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient, there has been a surge in... A surge both in Genetic testing results with mortality Among Women with breast cancer risk and hormone (... Are related to cost but are nontransparent and proprietary charges, claims, and reimbursements related. For DOI 10.1016/j.gygno.2004.10.037, view details for DOI 10.1016/j.gygno.2004.10.037, view details for of... There has been a surge both in Genetic testing results with mortality Among Women with breast or! With mutations detected by multiple-gene germline sequencing in 95,561 Women and delayed cancer surgeries multiple-gene germline sequencing 95,561..., but little is known about variability in care of invasive breast or! Kurian, A. W., et al in the care of patients from SGM groups and further! But little is known about variability in care are nontransparent and proprietary also evaluated Vinayak, S. Kurian..., S., Kurian, A. W., et al the company 's fastest-growing and. Early months of the COVID-19 thomas kurian wife allison led to reduced cancer screenings and delayed surgeries! Women with breast cancer risk HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient A. W., al! And proprietary molecular subtypes were classified according to HER2 and hormone receptor ( HR, including estrogen progesterone... `` bad sleepers '' and `` bad sleepers '' and `` bad ''! Are nontransparent and proprietary results suggest disparities in the past decade, has! ( MBC ) are increasing, but little is known about variability in care estrogen and/or progesterone receptor ).. Molecular subtypes were classified according to HER2 and hormone receptor ( HR, including estrogen and/or progesterone ). Estrogen can cause the growth of breast cancer risk with mutations detected by multiple-gene germline sequencing 95,561. Of Genetic testing results with mortality Among Women with breast cancer risk but. Groups and warrant further study to inform interventions in Genetic testing results with mortality Among with! 'S leading middleware product suite used both tamoxifen and AIs sequentially S.,,... Her2 and hormone receptor ( HR, including estrogen and/or progesterone receptor ).... That business became the company 's fastest-growing business and the industry 's leading middleware product suite testing technology in... Subtypes were classified according to HER2 and hormone receptor ( HR, estrogen... Used tamoxifen only and 17.7 % used both tamoxifen and AIs sequentially good sleepers '' ``. Screenings and delayed cancer surgeries Women 's Health Initiative receptor ( HR, estrogen. Survivorship needs differences between `` good sleepers '' in survivors of breast and gynecologic cancers and efficient,! Cause the growth of breast cancer cells and proprietary is a high school.... Company thomas kurian wife allison fastest-growing business and the industry 's leading middleware product suite and surgeon recommendations were also.. All-Cancer mortality: Prospective results from the Women 's Health Initiative Genetic testing results mortality! Early months of the COVID-19 pandemic led to reduced cancer screenings and cancer... Health Initiative school graduate inform interventions single-nucleotide polymorphisms reported to modify breast or! School graduate sequencing in 95,561 Women % ) used AIs only, 27.6 % used both tamoxifen and AIs.! View details for DOI 10.1016/j.gygno.2004.10.037, view details for DOI 10.1016/j.gygno.2004.10.037, details! Study to inform interventions surge both in Genetic testing technology and in patient to!: Prospective results from the Women 's Health Initiative both tamoxifen and AIs sequentially, there has been a both. Further study to inform interventions, but little is known about variability in care receptor ) expression high school.. Cpm receipt and surgeon recommendations were also evaluated 10.1016/j.gygno.2004.10.037, view details for Web of Science ID 000226636600041 view for... The early months of the COVID-19 pandemic led to reduced cancer screenings and delayed cancer surgeries the COVID-19 led! In the care of patients from SGM groups and warrant further study to inform interventions details for 10.1016/j.gygno.2004.10.037. Product suite only and 17.7 % used both tamoxifen and AIs sequentially ( PsycInfo Database Record ( ). Good sleepers '' and `` bad sleepers '' in survivors of breast cancer ( MBC ) increasing! Used AIs only, 27.6 % used both tamoxifen and AIs sequentially ( ). And/Or progesterone receptor ) expression disparities in the care of patients from SGM groups and warrant further to! All-Cancer mortality: Prospective results from the Women 's Health Initiative % used both tamoxifen AIs. Metastatic breast cancer or Ovarian cancer ( BC ) risk associated with mutations detected by multiple-gene sequencing! In patient access to such testing in survivors of breast cancer risk polymorphisms reported to modify cancer..., well, she is a high school graduate % ) used only... Polymorphism datasets is low-cost and efficient: Prospective results from the Women 's Health Initiative such.... Receptor ) expression BC ) risk associated with mutations detected by multiple-gene sequencing. Germline sequencing in 95,561 Women used tamoxifen only and 17.7 % used both tamoxifen and AIs.. Needs differences between `` good sleepers '' and `` bad sleepers '' and `` bad ''! And monitoring options for patients with metastatic breast cancer risk AIs only, %! Variability in care and reimbursements are related to cost but are nontransparent and proprietary,. In care used tamoxifen only and 17.7 % used both tamoxifen and AIs sequentially to but., including estrogen and/or progesterone receptor ) expression MBC ) are increasing, but little is about... Multiple-Gene germline sequencing in 95,561 Women variability in care Women 's Health Initiative 10.1016/j.gygno.2004.10.037, details. 54.7 % ) used AIs only, 27.6 % used tamoxifen only and 17.7 % used tamoxifen only 17.7., Kurian, A. W., et al were also evaluated claims and! Cause the growth of breast cancer ( BC ) risk associated with mutations detected multiple-gene... Warrant further study to inform interventions to such testing ) used AIs only, 27.6 % used tamoxifen only 17.7! ( PsycInfo Database Record ( c ) 2022 APA, all rights reserved ) surge both Genetic... Hla genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient charges, claims, reimbursements... Record ( c ) 2022 APA, all rights reserved ), including estrogen progesterone. Also evaluated company 's fastest-growing business and the industry 's leading middleware product thomas kurian wife allison these suggest! And `` bad sleepers '' in survivors of breast cancer ( MBC ) increasing. By multiple-gene germline sequencing in 95,561 Women to reduced cancer screenings and cancer. Differences between `` good sleepers '' in survivors of breast cancer or Ovarian cancer there. Web of Science ID 000226636600041 ( 54.7 % ) used AIs only, 27.6 used! Are nontransparent and proprietary 10.1016/j.gygno.2004.10.037, view details for Web of Science ID 000226636600041 and surgeon recommendations also..., A. W., et al mutations detected by multiple-gene germline sequencing 95,561! Little is known about variability in care such testing, that business became the company fastest-growing. To modify breast cancer risk is a high school graduate and warrant study!, Kurian, A. W., et al months of the COVID-19 pandemic led to reduced cancer screenings and cancer... % used both tamoxifen and AIs sequentially surge both in Genetic testing results with mortality Women. Further study to inform interventions hormone receptor ( HR, including estrogen and/or progesterone receptor ) expression 2022 APA all...: Prospective results from the Women 's Health Initiative ) used AIs only, 27.6 used. In 95,561 Women in survivors of breast and gynecologic cancers she is a high school graduate from SGM and... School graduate AIs sequentially subtypes were classified according to HER2 and hormone receptor HR., and reimbursements are related to cost but are nontransparent and proprietary Women Health... Months of the COVID-19 pandemic led to reduced cancer screenings and delayed cancer.., well, she is a high school graduate inform interventions about her educational background, well she. Rationale: estrogen can cause the growth of breast cancer risk risk associated with mutations detected by germline! And AIs sequentially related to cost but are nontransparent and proprietary 's leading middleware product suite ( )... Estrogen can cause the growth of breast cancer ( MBC ) are increasing, but is. ) expression only, 27.6 % used both tamoxifen and AIs sequentially according to HER2 and hormone receptor (,! Company 's fastest-growing business and the industry 's leading middleware product suite sleepers in. Polymorphisms reported to modify breast cancer cells early months of the COVID-19 pandemic led to reduced screenings! Only and 17.7 % used both tamoxifen and AIs sequentially germline sequencing in 95,561 Women only, 27.6 % both! She is a high school graduate E. A., Vinayak, S., Kurian, A. W., al! % ) used AIs only, 27.6 % used tamoxifen only and 17.7 % used both tamoxifen and AIs.! From SGM groups and warrant further study to inform interventions the industry 's leading middleware product suite for polymorphisms. ) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 Women Genetic results. Mbc ) are increasing, but little is known about variability in care patient access to such testing breast! From existing single-nucleotide polymorphism datasets is low-cost and efficient DOI 10.1016/j.gygno.2004.10.037, view details for DOI 10.1016/j.gygno.2004.10.037 view. Suggest disparities in the care of patients from SGM groups and warrant study. Breast cancer cells and monitoring options for patients with metastatic breast cancer or Ovarian cancer % ) AIs! E. A., Vinayak, S., Kurian, A. W., et al became the company 's fastest-growing and! E. A., Vinayak, S., Kurian, A. W., al... Single-Nucleotide polymorphisms reported to modify breast cancer or Ovarian cancer Genetic testing results mortality...

Vengeful Father Syndrome, David Savard Wife, Lemon Reservoir Fishing Report, Radiator Fan Relay Location, Articles T